Literature DB >> 8762083

Effects of hydroxyethylrutosides on hypoxia-induced activation of human endothelial cells in vitro.

D Janssens1, C Michiels, T Arnould, J Remacle.   

Abstract

1. A clinically available mixture of hydroxyethylrutosides (HR) was examined as inhibitors of endothelial cell activation by hypoxia in vitro. Thus, the effects of HR on ATP depletion, phospholipase A2 activation and neutrophil adherence were investigated in hypoxia-activated human umbilical vein endothelial cells in primary cell culture. 2. Our results show that HR inhibited two important steps of the activation of endothelial cells by hypoxia: the decrease in ATP content, which is the starting point of the process, and the activation of phospholipase A2 one enzyme responsible for the release of inflammatory mediators. This inhibition was dose-dependent with 70 to 90% inhibition at 500 micrograms ml-1 of HR. 3. In addition, hypoxia-activated endothelial cells increased their adhesiveness for neutrophils. This process could also be prevented in a dose-dependent manner if endothelial cells were incubated in the presence of HR. This inhibition was confirmed by a morphological study. 4. In conclusion, the results of this study suggest that a possible explanation for the improvement in venous insufficiency by HR observed clinically could be their ability to inhibit the activation of endothelial cells during blood stasis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8762083      PMCID: PMC1909748          DOI: 10.1111/j.1476-5381.1996.tb15443.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  21 in total

1.  Isolation of lymphocytes, granulocytes and macrophages.

Authors:  A Bøyum
Journal:  Scand J Immunol       Date:  1976-06       Impact factor: 3.487

2.  Causes of venous ulceration: a new hypothesis.

Authors:  P D Coleridge Smith; P Thomas; J H Scurr; J A Dormandy
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-18

3.  General practice treatment of symptoms of venous insufficiency with oxerutins. Results of a 660 patient multicentre study in the UK.

Authors:  T B Pulvertaft
Journal:  Vasa       Date:  1983       Impact factor: 1.961

4.  [Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients].

Authors:  A Balmer; C Limoni
Journal:  Vasa       Date:  1980       Impact factor: 1.961

5.  Recombinant tumor necrosis factor and interleukin-1 both stimulate human synovial cell arachidonic acid release and phospholipid metabolism.

Authors:  R W Godfrey; W J Johnson; S T Hoffstein
Journal:  Biochem Biophys Res Commun       Date:  1987-01-15       Impact factor: 3.575

6.  Inhibitory effect of the flavonoid O-(beta-hydroxyethyl)-rutoside on increased microvascular permeability induced by various agents in rat skin.

Authors:  B Gerdin; E Svensjö
Journal:  Int J Microcirc Clin Exp       Date:  1983

7.  Time course of the anti-oedematous effect of O-(beta-hydroxyethyl)-rutosides in healthy volunteers.

Authors:  D Rehn; G Hennings; W Nocker; W Diebschlag
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency.

Authors:  T Poynard; C Valterio
Journal:  Vasa       Date:  1994       Impact factor: 1.961

9.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.

Authors:  E A Jaffe; R L Nachman; C G Becker; C R Minick
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

10.  Suppression of the desquamating effect of smoking on the human endothelium by hydroxyethylrutosides.

Authors:  I Prerovský; J Hladovec
Journal:  Blood Vessels       Date:  1979
View more
  1 in total

1.  Effect of venotropic drugs on the respiratory activity of isolated mitochondria and in endothelial cells.

Authors:  D Janssens; E Delaive; A Houbion; F Eliaers; J Remacle; C Michiels
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.